Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery

Drug Development and Industrial Pharmacy

Volumn 40, Issue 7, 2014, Pages 869-878

  Sharma, Sumit ^a   Lohan, Shikha ^a   Murthy, R S R ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Chitosan nanoparticles; Nasal delivery; Nose to brain delivery; Rheology; Thermo reversible gel

Indexed keywords

CARBIDOPA; CHITOSAN; LEVODOPA; NANOPARTICLE; POLOXAMER; SODIUM CHLORIDE; ANTIPARKINSON AGENT; DRUG CARRIER; GEL;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DISPERSION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; FLOW KINETICS; GEL; GELATION; IN VITRO STUDY; IN VIVO STUDY; MUCOADHESION; NONHUMAN; OLFACTORY SYSTEM; PARTICLE SIZE; PERIPHERAL CIRCULATION; PROCESS OPTIMIZATION; RAT; TEMPERATURE; TRIGEMINAL NERVE; ADHESION; ANIMAL; CHEMISTRY; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; NOSE MUCOSA; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT;

ADHESIVENESS; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; DRUG LIBERATION; GELS; LEVODOPA; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NASAL MUCOSA; PARTICLE SIZE; POLOXAMER; RATS, WISTAR; RHEOLOGY; TEMPERATURE;

EID: 84902249410     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.789051     Document Type: Article

References (39)

1. Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expet Opin Drug Deliv 2009;6: 211-25.
2. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokin 1996; 30: 463-81.
3. Leenders KL, Poewe WH, Palmer AJ, et al. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986; 20: 258-62.
4. Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1973;242: 463-5.
5. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19: 997-1005.
6. Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol Today 1999;2: 49-59.
7. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11: 1-18.
8. McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76: 535-40.
9. Dahlin M, Jansson B, Bjork E. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 2001; 14: 75-80.
10. Westin U, Piras E, Jansson B, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005;24: 565-73.
11. Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expet Opin Drug Deliv 2008;5: 1159-68.
12. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002;54: 135-47.
13. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127: 97-109.
14. Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed 2011;6: 363-71.
15. Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358: 285-91.
16. Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on braintargeting. J Drug Target 2005;13: 317-24.
17. Desai S, Vidyasagar G, Shah V, Desai D. Preparation and in vitro characterisation of mucoadhesive microspheres of midazolam: nose to brain administration. Asian J Pharm Clin Res 2011;4: 100-2.
18. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible- mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006;7:E1-E7.
19. Bhavna SV, Ali M, Baboota S, Ali J. Preparation and characterization of chitosan nanoparticles for nose to brain delivery of a cholinesterase inhibitor. Indian J Pharm Sci 2007;69: 712-13.
20. Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47: 6-15.
21. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 2000;5: 77-85.
22. Smith JM, Dornish M, Wood EJ. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 2005;26: 3269-76.
23. Kim S, Kim JH, Jeon O, et al. Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm 2009;71: 420-30.
24. Bhardwaj R, Blanchard J. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J Pharm Sci 1996;85: 915-19.
25. Wang PL, Johnston TP. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 1993;47: 183-9.
26. Katakam M, Bell LN, Banga AK. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 1995;84: 713-16.
27. Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloid Surf B, Biointerf 2012;90: 21-7.
28. Schmolka IR. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 1972;6: 571-82.
29. Gilbert JC, Richardson JL, Davies MC, et al. The effect of solutes and polymers on the gelation properties of pluronic F-127 solutions for controlled drug delivery. J Control Release 1987;5: 113-18.
30. Choi HG, Oh YK, Kim C. In-situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm 1998;165: 23-32.
31. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70: 735-40.
32. Escobar-Chávez JJ, López-Cervantes M, Naïk A, et al. Applications of thermoreversible Pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharmaceut Sci 2006;9: 339-58.
33. Vadnere M, Amidon G, Haslam JL. Thermodynamics studies on gelsol transition of some pluronic polyols. Int J Pharm 1984;22: 207-18.
34. Hirai S, Yashike T, Mima H. Mechanism for the enhancement of the nasal absoption of insulin by surfactants. Int J Pharm 1978;9: 173-8.
35. Pisal S, Reddy P, Paradkar A, et al. Nasal melatonin gels using pluronic PF-127 for chronobiological treatment of sleep disorder. Ind J Biotech 2004;3: 369-77.
36. Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75: 186-93.
37. Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 2009;1788: 892-910.
38. De Lorenzo AJ. Electron microscopy of the olfactory and gustatory pathways. Ann Otol Rhinol Laryngol 1960;69: 410-20.
39. Oberdorster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004;16: 437-45.